<DOC>
	<DOCNO>NCT00219180</DOCNO>
	<brief_summary>To evaluate efficacy safety aliskiren alone combination valsartan give patient essential hypertension</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy Safety Aliskiren ( 150mg &amp; 300mg ) Administered Alone Combo With Valsartan ( 160mg 320mg ) Patients With High Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Inclusion Criteria Patients essential hypertension Patients eligible able participate study Exclusion Criteria Severe hypertension History evidence secondary form hypertension History Hypertensive encephalopathy cerebrovascular accident Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Hypertension , Aliskiren</keyword>
</DOC>